Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

The earnings call presents a mixed picture. While there are some positive aspects such as increased gross margins and strategic focus areas, there are significant concerns. The company faces liquidity constraints, operating losses, and supply chain risks. The international market challenges and increased operating expenses add to the negative sentiment. Despite the optimistic guidance for 2026, the current financial health and operational challenges are likely to weigh on the stock price, leading to a negative sentiment prediction.

Key Financial Performance

Fourth Quarter Revenue $2.4 million, a 4% increase compared to the prior year quarter and a 9% increase sequentially. The year-over-year improvement was driven by a 208% increase in U.S. console sales with 8 units sold compared to 3 in the prior year period and an 11% circuit average selling price increase.

International Sales Increased 59% year-over-year, largely as a result of last time buys from distributors whose territories we were exiting.

Critical Care Revenue Declined 24% year-over-year.

Gross Margin (Fourth Quarter) 68.2%, an improvement of 9.9 percentage points compared to the prior year quarter.

Operating Expenses (Fourth Quarter) $4.1 million, representing a $0.4 million increase compared to the prior year quarter. The year-over-year increase reflects higher professional services, recruiting activity and targeted development initiatives.

Operating Loss (Fourth Quarter) $2.4 million, flat with the prior year quarter.

Net Loss Attributable to Common Shareholders (Fourth Quarter) $2.4 million.

Full Year Revenue $8.3 million, a 5% decrease compared to the prior year. The year-over-year decline reflects lower consumables utilization, lower U.S. console average selling prices, reduced international contributions following strategic rationalization and prior year SeaStar sales prior to that agreement termination.

Heart Failure and Pediatrics Revenue Grew 8% and 14% year-over-year, respectively, partially offset by a 19% decline in Critical Care.

Full Year Gross Margin 62%, 3 percentage points higher than the prior year.

Operating Expenses (Full Year) $16.2 million, slightly lower than the prior year, reflecting improved expense discipline and forecasting rigor.

Net Loss Attributable to Common Shareholders (Full Year) $17.5 million, which includes a $6.4 million noncash warrant valuation expense and approximately $0.3 million in executive severance expense.

Full Year Cash Utilization Approximately $10.9 million.

Year-End Cash Position Approximately $1.2 million in cash and no outstanding debt.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

Pediatric Program Expansion: Expanded intellectual property supporting pediatric device development and received a National Institute of Health Grant to advance this program.

International Commercial Strategy: Reduced exposure in certain markets and redirected focus towards geographies with more predictable clinical demand and commercial conversion.

Manufacturing Transition: Transitioned manufacturing to KDI Precision Manufacturing to enhance operational predictability, supply chain foundation, and structural margin performance.

Expense Management: Full year operating expenses were reduced by $400,000 compared to the prior year, reflecting tighter expense management and improved forecasting discipline.

Strategic Positioning: Shifted focus to the cardiorenal continuum, emphasizing precision volume management for cardiac and renal conditions.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Revenue Decline: Full year revenue declined by 5% compared to 2024, reflecting lower consumables utilization, reduced international contributions, and lower U.S. console average selling prices.

Critical Care Revenue Decline: Critical Care revenue declined by 24% in the fourth quarter and 19% for the full year, indicating challenges in this segment.

International Market Challenges: Portions of the international business generated inconsistent returns and required disproportionate resources, leading to reduced exposure in certain markets.

Liquidity Constraints: The company ended the year with $1.2 million in cash and no outstanding debt, highlighting tight liquidity and reliance on financing activities to support operations.

Operating Loss: The company reported an operating loss of $2.4 million for the fourth quarter and $17.5 million net loss for the full year, including noncash warrant valuation and severance expenses.

Supply Chain Transition Risks: The transition of manufacturing to KDI Precision Manufacturing was a significant operational undertaking, requiring coordination across supply chain, quality systems, and production leadership, posing risks to operational predictability.

Expense Management Challenges: Operating expenses increased by $0.4 million in the fourth quarter due to higher professional services, recruiting activity, and development initiatives, despite efforts to improve expense discipline.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Revenue Expectations: The company anticipates focusing on geographies with predictable clinical demand and commercial conversion, which may influence revenue growth in 2026.

Margin Projections: Gross margin consistency remains a priority for 2026, building on the 68.2% gross margin achieved in Q4 2025.

Capital Expenditures and Liquidity: The company plans to maintain disciplined capital allocation and liquidity management, with a focus on prudent capital deployment in 2026.

Market Trends and Business Segment Performance: Growth in heart failure and pediatrics segments is expected to continue, with these areas showing 8% and 14% growth respectively in 2025. The company will prioritize accounts and patient populations with demonstrable clinical pull and economic value.

Strategic Plans: The company will continue to focus on the cardiorenal continuum, emphasizing precision volume management for cardiac and renal conditions. The pediatric program will be further developed, supported by strengthened intellectual property and NIH funding.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Can you elaborate on the operational changes and refocus of the business, including the sales force and the integration of Rendiatech products?

A:In 2025, the company reinforced its direct sales team, recovering from a decline in account territories by hiring account managers and clinical specialists. This led to growth in the second half of the year and into 2026. The company addressed product recall and quality issues by partnering with KDI Precision Manufacturing, stabilizing supply and quality. They exited the EU market to reduce cash burn and terminated the REVERSE-HF clinical trial to save $3 million, focusing instead on publishing positive results from completed data. The NIH grant supports pediatric renal replacement therapy development. The Rendiatech acquisition adds ICU-focused technology for measuring renal output and analytes, enhancing kidney health monitoring.

Q:Is the focus for 2026 on increasing utilization within existing accounts or acquiring new accounts, and what is the current status of the sales force?

A:The focus for 2026 is on increasing utilization within existing accounts, particularly in Critical Care and ICU settings, while continuing to support heart failure and pediatric nephrology. The sales team consists of 24 individuals, which meets the budgeted headcount for 2025, and this number is expected to remain constant through 2026. The Rendiatech acquisition is seen as a way to enhance utilization within existing accounts.

Q:Review of Unclear Management Responses

A:None of the questions were avoided or lacked clarity. Management provided detailed and specific responses to all questions.

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

NUWE Transcript

Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript

Unknown3-10

Nuwellis, Inc. (NUWE) Q3 2025 Earnings Call Prepared Remarks Transcript

Unknown11-12

The earnings call reveals several challenges: a 6% revenue decline, reduced gross margins, increased operating expenses, and a higher operating loss. Despite some positive aspects like sequential revenue growth and a focus on U.S. market expansion, the termination of international operations and dependency on the U.S. market pose risks. The cash position is limited, and manufacturing transition risks exist. With no new partnerships or positive shareholder return plans discussed, the overall sentiment is negative, likely leading to a -2% to -8% stock price movement.

Nuwellis, Inc. (NUWE) Q2 2025 Earnings Call Transcript

Unknown8-14

The earnings call presents a mixed picture. While there is growth in pediatrics and improved reimbursement for heart failure, the overall financial performance is concerning. Revenue declined by 21% due to a product back order, and margins fell significantly. The termination of the REVERSE-HF trial and increased net losses further add to the negative sentiment. Despite the resolution of the sterilization issue and potential in pediatrics, the financial challenges and operational risks outweigh the positives, leading to a negative outlook for the stock.

Nuwellis, Inc. (NASDAQ:NUWE) Q1 2025 Earnings Call Transcript

Unknown5-14

The earnings call reveals mixed signals. While there are positive developments like increased reimbursement rates and outpatient market entry, there are concerns about declining international sales, margin reduction, and customer dependency risks. The Q&A section highlighted some unresolved issues, such as the lack of clarity on revenue drops and vague timelines for clinical trials. Despite financial improvements in operating loss and expenses, the absence of a share repurchase program and manufacturing challenges temper expectations. Overall, these factors suggest a neutral impact on the stock price over the next two weeks.

NUWE Report

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.